Boenning & Scattergood’s Novartis NVS Stock Holding History

Boenning & Scattergood’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$509K	Buy	5,798 +2	+0%	+$168	0.08%	248
2022 Q3	$441K	Sell	5,796 -7	-0.1%	-$580	0.09%	244
2022 Q2	$491K	Buy	5,803 +5	+0.1%	+$439	0.09%	227
2022 Q1	$509K	Sell	5,798 -948	-14%	-$82.1K	0.08%	248
2021 Q4	$590K	Buy	6,746 +500	+8%	+$41.5K	0.09%	226
2021 Q3	$510K	Buy	6,246 +750	+14%	+$67.5K	0.09%	235
2021 Q2	$501K	Hold	5,496	–	–	0.09%	243
2021 Q1	$470K	Buy	5,496 +293	+6%	+$26.3K	0.09%	241
2020 Q4	$491K	Buy	5,203 +40	+0.8%	+$3.5K	0.1%	209
2020 Q3	$449K	Buy	5,163 +56	+1%	+$4.85K	0.11%	202
2020 Q2	$446K	Sell	5,107 -654	-11%	-$56.5K	0.12%	190
2020 Q1	$475K	Sell	5,761 -543	-9%	-$48.4K	0.16%	152
2019 Q4	$597K	Hold	6,304	–	–	0.15%	162
2019 Q3	$548K	Sell	6,304 -4	-0.1%	-$359	0.16%	157
2019 Q2	$576K	Sell	6,308 -732	-10%	-$62K	0.17%	152
2019 Q1	$606K	Buy	7,040 +17	+0.2%	+$1.36K	0.18%	143
2018 Q4	$540K	Hold	7,023	–	–	0.19%	145
2018 Q3	$542K	Buy	7,023 +1,395	+25%	+$103K	0.17%	151
2018 Q2	$381K	Buy	+5,628	New	+$388K	0.13%	197

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Boenning & Scattergood's NVS Position: Q4 2022 in Review

Boenning & Scattergood increased its Novartis (NVS) stake by 0.03% in Q4 2022, buying an estimated $168 and bringing the position to 5,798 shares worth $509K. The position accounts for 0.08% of the portfolio, ranked #248.

Boenning & Scattergood first reported a position in NVS in Q2 2018 and has held it in 19 quarters since. The position peaked at $606K in Q1 2019. 1,182 funds tracked by Wall St. Rank hold NVS as of Q4 2022.

Boenning & Scattergood held 5,798 shares of Novartis worth $509K as of Q4 2022.
Boenning & Scattergood bought 2 Novartis shares in Q4 2022, an estimated $168.
Novartis made up 0.08% of Boenning & Scattergood's portfolio in Q4 2022, its #248 holding.
Boenning & Scattergood first reported a position in Novartis in Q2 2018 and has held it in 19 quarters since.
Boenning & Scattergood's Novartis position peaked at $606K in Q1 2019.
1,182 funds tracked by Wall St. Rank held Novartis as of Q4 2022.

Based on Boenning & Scattergood's 13F filing for Q4 2022, filed 26 Jan 2023.